NASDAQ
ALLO
Last Price
US $2.08
KEY FIGURES
MKT CAP
$0.5B
EPS
TTM
$-0.72
PEG
TTM
-
P/E
TTM
N/M
P/S
TTM
-
YIELD
0.00%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
-56.45%
Return on equity
ROIC: -50.58%
Valuation History
-2.8X
Price to Earnings
EV/EBITDA: -3.5X
Cash flow
Profit margin
-
(FY vs FY)
EBITDA Y/Y
6.11%
(FY vs FY)
Cash flow Y/Y
3.89%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $2.08
—
Default assumptions
EBITDA Multiple
Fair Value
Market $2.08
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Allogene Therapeutics, Inc. cash flow to debt ratio of -179.27% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial stability - Healthy cash flow growth.
Allogene Therapeutics, Inc.'s free cash flow has increased -25.55% from $-200.99M last year to $-149.63M, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
Allogene Therapeutics, Inc.'s debt to equity ratio is 0.29, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial risk - Healthy debt to equity ratio development.
Allogene Therapeutics, Inc.'s debt has increased relative to shareholder equity from 0.21 last year to 0.29 today, signaling weakened financials
Financial risk - Net debt/EBITDA.
Allogene Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Allogene Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial stability - Profit margin growth.
Allogene Therapeutics, Inc.'s profit margin has increased (-100.00%) in the last year from -1.17M% to 0.00%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Allogene Therapeutics, Inc.'s short-term assets of $257.75M exceed its short-term liabilities of $32.51M
Decreasing performance - ROA.
Allogene Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Allogene Therapeutics, Inc.'s return on equity of -56.45%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Allogene Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Allogene Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Allogene Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Allogene Therapeutics, Inc. has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
Allogene Therapeutics, Inc.'s yearly earnings has increased -25.90% since last year from $-257.59M to $-190.89M, signaling increasing performance
Decreasing performance - Healthy revenue growth.
Allogene Therapeutics, Inc.'s yearly revenue has decreased -100.00% since last year from $22.00K to $0.00, signaling decreasing performance
Decreasing performance - ROIC.
ROIC -50.58% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Allogene Therapeutics, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years
Decreasing performance - Revenue consistency.
Allogene Therapeutics, Inc. had revenue growth in only 1.00 out of 5 years, indicating inconsistent revenue performance
Decreasing performance - ROE consistency.
Allogene Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Allogene Therapeutics, Inc. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Allogene Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Allogene Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Allogene Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Allogene Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Allogene Therapeutics, Inc. has a price-to-book ratio of 1.84x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Overvalued - P/S ratio.
Allogene Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue